Donald Bodenner
Concepts (286)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Thyroid Neoplasms | 14 | 2017 | 112 | 2.000 |
Why?
| Thyroidectomy | 13 | 2019 | 60 | 1.840 |
Why?
| Thyroid Diseases | 8 | 2019 | 27 | 1.460 |
Why?
| Parathyroidectomy | 8 | 2018 | 46 | 1.310 |
Why?
| Parathyroid Neoplasms | 5 | 2015 | 28 | 1.090 |
Why?
| Thyroid Gland | 8 | 2017 | 75 | 1.090 |
Why?
| Parathyroid Hormone | 8 | 2019 | 149 | 0.960 |
Why?
| Vitamin D Deficiency | 5 | 2019 | 44 | 0.960 |
Why?
| Adenoma | 4 | 2017 | 113 | 0.960 |
Why?
| Vitamin D | 4 | 2015 | 87 | 0.820 |
Why?
| Fluorodeoxyglucose F18 | 6 | 2013 | 189 | 0.750 |
Why?
| Positron-Emission Tomography | 7 | 2013 | 292 | 0.730 |
Why?
| Radiopharmaceuticals | 7 | 2015 | 204 | 0.720 |
Why?
| Carcinoma, Papillary | 4 | 2017 | 47 | 0.710 |
Why?
| Ambulatory Surgical Procedures | 4 | 2014 | 52 | 0.690 |
Why?
| Hyperparathyroidism, Primary | 4 | 2018 | 36 | 0.660 |
Why?
| Iodine Radioisotopes | 4 | 2015 | 35 | 0.620 |
Why?
| Hyperparathyroidism | 2 | 2015 | 31 | 0.600 |
Why?
| Megestrol Acetate | 2 | 2007 | 17 | 0.530 |
Why?
| Parathyroid Diseases | 2 | 2016 | 5 | 0.530 |
Why?
| Bone Density Conservation Agents | 2 | 2007 | 74 | 0.510 |
Why?
| Nursing Homes | 2 | 2007 | 111 | 0.510 |
Why?
| Incidental Findings | 3 | 2013 | 39 | 0.490 |
Why?
| Proton Pump Inhibitors | 1 | 2015 | 83 | 0.480 |
Why?
| Diphosphonates | 1 | 2015 | 90 | 0.470 |
Why?
| Academic Medical Centers | 2 | 2012 | 149 | 0.460 |
Why?
| Thyroglobulin | 2 | 2013 | 7 | 0.460 |
Why?
| Aged | 20 | 2017 | 9741 | 0.440 |
Why?
| Parathyroid Glands | 5 | 2018 | 21 | 0.430 |
Why?
| Carcinoma, Medullary | 2 | 2010 | 12 | 0.430 |
Why?
| Middle Aged | 26 | 2017 | 12611 | 0.430 |
Why?
| Hypothyroidism | 2 | 2011 | 56 | 0.390 |
Why?
| Male | 32 | 2019 | 25907 | 0.390 |
Why?
| Retrospective Studies | 14 | 2019 | 6263 | 0.380 |
Why?
| Calcitonin | 2 | 2010 | 30 | 0.370 |
Why?
| Postoperative Complications | 5 | 2018 | 1033 | 0.370 |
Why?
| Humans | 49 | 2019 | 50503 | 0.360 |
Why?
| Carcinoma | 2 | 2012 | 137 | 0.350 |
Why?
| Algorithms | 1 | 2013 | 625 | 0.340 |
Why?
| Thyroid Nodule | 3 | 2017 | 31 | 0.330 |
Why?
| Female | 31 | 2019 | 27081 | 0.320 |
Why?
| Weight Loss | 2 | 2009 | 245 | 0.310 |
Why?
| Aged, 80 and over | 10 | 2017 | 3226 | 0.290 |
Why?
| Appetite Stimulants | 1 | 2007 | 5 | 0.280 |
Why?
| Cachexia | 1 | 2007 | 25 | 0.280 |
Why?
| Receptors, Estrogen | 2 | 2005 | 132 | 0.280 |
Why?
| Teriparatide | 1 | 2007 | 10 | 0.270 |
Why?
| Four-Dimensional Computed Tomography | 2 | 2017 | 28 | 0.260 |
Why?
| Hypocalcemia | 2 | 2016 | 12 | 0.250 |
Why?
| Transcriptional Activation | 2 | 2005 | 119 | 0.250 |
Why?
| Calcium | 3 | 2018 | 398 | 0.250 |
Why?
| Pituitary Hormones, Anterior | 1 | 2005 | 4 | 0.250 |
Why?
| Phenylurea Compounds | 2 | 2015 | 15 | 0.250 |
Why?
| Hormones | 1 | 2005 | 57 | 0.250 |
Why?
| Osteoporosis | 1 | 2007 | 156 | 0.240 |
Why?
| Quinolines | 2 | 2015 | 41 | 0.240 |
Why?
| Pituitary Gland | 1 | 2005 | 85 | 0.240 |
Why?
| Receptors, Thyrotropin | 2 | 2007 | 8 | 0.230 |
Why?
| Interleukin-6 | 1 | 2005 | 261 | 0.230 |
Why?
| NF-kappa B | 1 | 2005 | 315 | 0.220 |
Why?
| Protein Kinase Inhibitors | 2 | 2015 | 204 | 0.220 |
Why?
| Biopsy, Fine-Needle | 5 | 2011 | 108 | 0.210 |
Why?
| Illinois | 2 | 2013 | 10 | 0.210 |
Why?
| Treatment Outcome | 8 | 2015 | 5283 | 0.200 |
Why?
| Adult | 13 | 2017 | 13577 | 0.190 |
Why?
| Gene Expression Regulation | 3 | 2005 | 955 | 0.190 |
Why?
| Aging | 1 | 2005 | 693 | 0.170 |
Why?
| Young Adult | 7 | 2015 | 4102 | 0.170 |
Why?
| Follow-Up Studies | 3 | 2013 | 2242 | 0.160 |
Why?
| Hyperparathyroidism, Secondary | 1 | 2019 | 4 | 0.160 |
Why?
| Postoperative Period | 3 | 2015 | 171 | 0.160 |
Why?
| Thyroid Hormones | 1 | 1998 | 20 | 0.160 |
Why?
| Receptors, Cytoplasmic and Nuclear | 1 | 1998 | 68 | 0.150 |
Why?
| Receptors, Cell Surface | 1 | 1998 | 116 | 0.150 |
Why?
| Preoperative Care | 2 | 2018 | 169 | 0.150 |
Why?
| Vitamins | 2 | 2018 | 63 | 0.150 |
Why?
| Patient Discharge | 3 | 2016 | 321 | 0.150 |
Why?
| Intraoperative Complications | 1 | 2019 | 114 | 0.140 |
Why?
| Insulin Resistance | 2 | 2009 | 268 | 0.140 |
Why?
| United States | 5 | 2015 | 4955 | 0.140 |
Why?
| Antineoplastic Agents | 2 | 2015 | 1172 | 0.140 |
Why?
| Prospective Studies | 2 | 2013 | 2378 | 0.140 |
Why?
| Predictive Value of Tests | 3 | 2015 | 930 | 0.130 |
Why?
| Reoperation | 1 | 2018 | 460 | 0.130 |
Why?
| Incidence | 2 | 2011 | 1032 | 0.130 |
Why?
| Adolescent | 5 | 2015 | 6443 | 0.120 |
Why?
| Hypoparathyroidism | 1 | 2015 | 5 | 0.120 |
Why?
| Carcinoma, Neuroendocrine | 1 | 2015 | 23 | 0.120 |
Why?
| Creatinine | 1 | 2015 | 145 | 0.120 |
Why?
| Costs and Cost Analysis | 2 | 2014 | 90 | 0.120 |
Why?
| Tomography, Emission-Computed, Single-Photon | 1 | 2015 | 52 | 0.120 |
Why?
| Lymph Nodes | 1 | 2017 | 257 | 0.120 |
Why?
| Disease Progression | 3 | 2015 | 829 | 0.120 |
Why?
| Molecular Targeted Therapy | 1 | 2015 | 123 | 0.120 |
Why?
| Diagnosis, Differential | 6 | 2018 | 1033 | 0.110 |
Why?
| Ambulatory Care | 1 | 2016 | 230 | 0.110 |
Why?
| Neoplasm Metastasis | 2 | 2015 | 232 | 0.110 |
Why?
| Hospitals, University | 1 | 2014 | 77 | 0.110 |
Why?
| Child, Preschool | 2 | 2013 | 3942 | 0.110 |
Why?
| Sensitivity and Specificity | 2 | 2013 | 859 | 0.110 |
Why?
| Exercise | 2 | 2009 | 516 | 0.110 |
Why?
| Liver | 2 | 2009 | 1132 | 0.110 |
Why?
| Drug Administration Schedule | 1 | 2013 | 370 | 0.100 |
Why?
| Hospitals, Teaching | 1 | 2013 | 54 | 0.100 |
Why?
| Technetium | 1 | 2012 | 9 | 0.100 |
Why?
| Administration, Oral | 1 | 2013 | 434 | 0.100 |
Why?
| Preoperative Period | 1 | 2012 | 48 | 0.100 |
Why?
| Patient Compliance | 1 | 2013 | 233 | 0.100 |
Why?
| Radionuclide Imaging | 1 | 2012 | 116 | 0.100 |
Why?
| Outpatients | 1 | 2013 | 117 | 0.100 |
Why?
| Clinical Competence | 2 | 2018 | 398 | 0.100 |
Why?
| Hospital Charges | 1 | 2012 | 44 | 0.100 |
Why?
| Tumor Burden | 1 | 2012 | 130 | 0.100 |
Why?
| Struma Ovarii | 1 | 2012 | 5 | 0.100 |
Why?
| Cost Savings | 1 | 2012 | 57 | 0.100 |
Why?
| Prognosis | 3 | 2015 | 1978 | 0.100 |
Why?
| Child | 3 | 2013 | 6906 | 0.100 |
Why?
| Promoter Regions, Genetic | 4 | 2007 | 465 | 0.100 |
Why?
| Ovariectomy | 1 | 2012 | 115 | 0.090 |
Why?
| Immunohistochemistry | 2 | 2012 | 957 | 0.090 |
Why?
| Obesity | 2 | 2009 | 1121 | 0.090 |
Why?
| Chromogranin A | 1 | 2010 | 5 | 0.090 |
Why?
| Dose-Response Relationship, Drug | 1 | 2013 | 1372 | 0.090 |
Why?
| Radiation Monitoring | 1 | 2010 | 7 | 0.090 |
Why?
| Checklist | 1 | 2010 | 29 | 0.090 |
Why?
| Inpatients | 1 | 2011 | 193 | 0.080 |
Why?
| Radiosurgery | 1 | 2011 | 123 | 0.080 |
Why?
| Fatal Outcome | 1 | 2010 | 197 | 0.080 |
Why?
| Databases, Factual | 1 | 2013 | 673 | 0.080 |
Why?
| HeLa Cells | 4 | 2005 | 247 | 0.080 |
Why?
| Multiple Endocrine Neoplasia Type 2a | 1 | 2009 | 5 | 0.080 |
Why?
| Caloric Restriction | 1 | 2009 | 35 | 0.080 |
Why?
| Ultrasonography | 4 | 2015 | 435 | 0.080 |
Why?
| Proto-Oncogene Proteins c-ret | 1 | 2009 | 33 | 0.080 |
Why?
| Intra-Abdominal Fat | 1 | 2009 | 21 | 0.080 |
Why?
| General Surgery | 1 | 2010 | 108 | 0.080 |
Why?
| Occupational Exposure | 1 | 2010 | 113 | 0.080 |
Why?
| Blastomycosis | 1 | 2008 | 34 | 0.070 |
Why?
| Symporters | 1 | 2007 | 17 | 0.070 |
Why?
| Adenoma, Oxyphilic | 1 | 2007 | 11 | 0.070 |
Why?
| Ovarian Neoplasms | 1 | 2012 | 450 | 0.070 |
Why?
| Time Factors | 3 | 2015 | 2935 | 0.070 |
Why?
| Severity of Illness Index | 1 | 2011 | 978 | 0.070 |
Why?
| Anorexia | 1 | 2007 | 7 | 0.070 |
Why?
| Whole Body Imaging | 1 | 2007 | 26 | 0.070 |
Why?
| Adiposity | 1 | 2009 | 137 | 0.070 |
Why?
| DNA, Neoplasm | 1 | 2007 | 143 | 0.070 |
Why?
| Base Sequence | 3 | 2005 | 639 | 0.070 |
Why?
| Calcifediol | 1 | 2006 | 8 | 0.070 |
Why?
| Practice Management, Medical | 1 | 2006 | 10 | 0.070 |
Why?
| Calcium Carbonate | 1 | 2006 | 11 | 0.070 |
Why?
| Medical Audit | 1 | 2006 | 21 | 0.070 |
Why?
| Drug Utilization Review | 1 | 2006 | 23 | 0.070 |
Why?
| Drug Monitoring | 1 | 2006 | 79 | 0.070 |
Why?
| Head | 1 | 2006 | 70 | 0.070 |
Why?
| Cross-Sectional Studies | 2 | 2014 | 1610 | 0.070 |
Why?
| Geriatrics | 1 | 2006 | 45 | 0.070 |
Why?
| Thyrotropin | 3 | 2002 | 49 | 0.070 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2010 | 833 | 0.070 |
Why?
| Otolaryngology | 1 | 2006 | 61 | 0.060 |
Why?
| Body Mass Index | 2 | 2009 | 677 | 0.060 |
Why?
| Neck | 1 | 2006 | 99 | 0.060 |
Why?
| Proportional Hazards Models | 1 | 2007 | 415 | 0.060 |
Why?
| Progesterone Congeners | 1 | 2005 | 5 | 0.060 |
Why?
| Body Fat Distribution | 1 | 2005 | 9 | 0.060 |
Why?
| Freezing | 1 | 2005 | 16 | 0.060 |
Why?
| Faculty, Medical | 1 | 2006 | 92 | 0.060 |
Why?
| Arkansas | 2 | 2014 | 1985 | 0.060 |
Why?
| Serum | 1 | 2005 | 32 | 0.060 |
Why?
| Fractures, Bone | 1 | 2006 | 109 | 0.060 |
Why?
| Survival Analysis | 1 | 2007 | 661 | 0.060 |
Why?
| DNA Primers | 1 | 2005 | 206 | 0.060 |
Why?
| Reproducibility of Results | 3 | 2017 | 1197 | 0.060 |
Why?
| Internship and Residency | 1 | 2010 | 447 | 0.060 |
Why?
| Nuclear Proteins | 1 | 2005 | 238 | 0.060 |
Why?
| Protein Binding | 1 | 2005 | 654 | 0.050 |
Why?
| Infant | 1 | 2012 | 3628 | 0.050 |
Why?
| Proto-Oncogene Proteins c-jun | 2 | 1993 | 77 | 0.050 |
Why?
| ROC Curve | 2 | 2015 | 226 | 0.050 |
Why?
| Patient Selection | 2 | 2018 | 259 | 0.050 |
Why?
| Intraoperative Period | 2 | 2015 | 45 | 0.050 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2005 | 573 | 0.050 |
Why?
| Mutation | 2 | 2017 | 1280 | 0.050 |
Why?
| Tongue Diseases | 1 | 2001 | 7 | 0.050 |
Why?
| Choristoma | 1 | 2001 | 24 | 0.050 |
Why?
| Receptors, Androgen | 1 | 2001 | 45 | 0.050 |
Why?
| Tomography, X-Ray Computed | 3 | 2012 | 1164 | 0.040 |
Why?
| DNA-Binding Proteins | 2 | 1993 | 418 | 0.040 |
Why?
| Thalidomide | 1 | 2002 | 378 | 0.040 |
Why?
| Transcription Factors | 2 | 1993 | 565 | 0.040 |
Why?
| Cohort Studies | 2 | 2015 | 1452 | 0.040 |
Why?
| Glucagon | 2 | 2009 | 23 | 0.040 |
Why?
| Monitoring, Intraoperative | 1 | 2019 | 54 | 0.040 |
Why?
| Cholecalciferol | 1 | 2018 | 22 | 0.040 |
Why?
| GTP-Binding Proteins | 1 | 1998 | 91 | 0.040 |
Why?
| Hospitals, High-Volume | 1 | 2018 | 25 | 0.040 |
Why?
| Medical History Taking | 1 | 2018 | 48 | 0.040 |
Why?
| Autoantibodies | 1 | 1998 | 117 | 0.040 |
Why?
| Risk Factors | 1 | 2006 | 3724 | 0.040 |
Why?
| Pilot Projects | 2 | 2010 | 698 | 0.040 |
Why?
| Methylene Blue | 1 | 2017 | 9 | 0.040 |
Why?
| Lymphatic System | 1 | 2017 | 13 | 0.040 |
Why?
| Societies, Medical | 1 | 2018 | 187 | 0.040 |
Why?
| Animals, Genetically Modified | 1 | 2017 | 48 | 0.030 |
Why?
| Coloring Agents | 1 | 2017 | 66 | 0.030 |
Why?
| Mice, Inbred Strains | 1 | 2017 | 160 | 0.030 |
Why?
| Insulin | 2 | 2009 | 467 | 0.030 |
Why?
| Proto-Oncogene Proteins B-raf | 1 | 2017 | 80 | 0.030 |
Why?
| Recurrence | 1 | 2018 | 659 | 0.030 |
Why?
| Lymphatic Metastasis | 1 | 2017 | 222 | 0.030 |
Why?
| Bone Density | 1 | 2018 | 386 | 0.030 |
Why?
| Technetium Tc 99m Sestamibi | 1 | 2015 | 18 | 0.030 |
Why?
| Retreatment | 1 | 2015 | 56 | 0.030 |
Why?
| Brachial Plexus | 1 | 2015 | 11 | 0.030 |
Why?
| Endocrinology | 1 | 2015 | 11 | 0.030 |
Why?
| Axilla | 1 | 2015 | 91 | 0.030 |
Why?
| Hematoma | 1 | 2015 | 64 | 0.030 |
Why?
| Signal Transduction | 1 | 2001 | 1624 | 0.030 |
Why?
| Transplantation, Autologous | 1 | 2015 | 481 | 0.030 |
Why?
| Neoplasm Staging | 1 | 2015 | 746 | 0.030 |
Why?
| Hernia, Abdominal | 1 | 2012 | 4 | 0.020 |
Why?
| Activating Transcription Factor 1 | 1 | 2012 | 22 | 0.020 |
Why?
| Delayed Diagnosis | 1 | 2012 | 24 | 0.020 |
Why?
| Mice | 2 | 2017 | 5687 | 0.020 |
Why?
| Ribs | 1 | 2010 | 15 | 0.020 |
Why?
| Thoracotomy | 1 | 2010 | 35 | 0.020 |
Why?
| Mediastinal Neoplasms | 1 | 2010 | 16 | 0.020 |
Why?
| Neck Dissection | 1 | 2010 | 30 | 0.020 |
Why?
| Hypercalcemia | 1 | 2010 | 33 | 0.020 |
Why?
| Feasibility Studies | 1 | 2011 | 390 | 0.020 |
Why?
| Gas Chromatography-Mass Spectrometry | 1 | 2009 | 68 | 0.020 |
Why?
| Hospitalization | 1 | 2014 | 675 | 0.020 |
Why?
| Octreotide | 1 | 2009 | 9 | 0.020 |
Why?
| Prevalence | 1 | 2012 | 971 | 0.020 |
Why?
| Glucose Tolerance Test | 1 | 2009 | 58 | 0.020 |
Why?
| Adiponectin | 1 | 2009 | 46 | 0.020 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 234 | 0.020 |
Why?
| Absorptiometry, Photon | 1 | 2009 | 155 | 0.020 |
Why?
| Postmenopause | 1 | 2009 | 96 | 0.020 |
Why?
| Eye | 1 | 2008 | 24 | 0.020 |
Why?
| Bone Neoplasms | 1 | 2010 | 179 | 0.020 |
Why?
| Iodine | 1 | 2007 | 9 | 0.020 |
Why?
| Methylation | 1 | 2007 | 118 | 0.020 |
Why?
| Body Weight | 1 | 2009 | 517 | 0.020 |
Why?
| Neoplasm Recurrence, Local | 1 | 2011 | 629 | 0.020 |
Why?
| Multiple Myeloma | 1 | 2002 | 2998 | 0.020 |
Why?
| Overweight | 1 | 2009 | 215 | 0.020 |
Why?
| Current Procedural Terminology | 1 | 2006 | 7 | 0.020 |
Why?
| Insurance, Health, Reimbursement | 1 | 2006 | 24 | 0.020 |
Why?
| Office Visits | 1 | 2006 | 44 | 0.020 |
Why?
| Polymerase Chain Reaction | 1 | 2007 | 449 | 0.020 |
Why?
| Genetic Predisposition to Disease | 1 | 2009 | 511 | 0.020 |
Why?
| Blood Glucose | 1 | 2009 | 446 | 0.020 |
Why?
| Animals | 2 | 2017 | 13124 | 0.020 |
Why?
| Risk Assessment | 1 | 2010 | 1270 | 0.020 |
Why?
| Lung | 1 | 2008 | 504 | 0.010 |
Why?
| Thyrotropin-Releasing Hormone | 2 | 1993 | 5 | 0.010 |
Why?
| Tetradecanoylphorbol Acetate | 2 | 1993 | 47 | 0.010 |
Why?
| Transcription Factor Pit-1 | 2 | 1993 | 20 | 0.010 |
Why?
| Muscle, Skeletal | 1 | 2009 | 784 | 0.010 |
Why?
| Thyroid Function Tests | 1 | 2002 | 25 | 0.010 |
Why?
| Molecular Sequence Data | 2 | 1993 | 778 | 0.010 |
Why?
| src Homology Domains | 1 | 2001 | 9 | 0.010 |
Why?
| Airway Obstruction | 1 | 2001 | 47 | 0.010 |
Why?
| Androgens | 1 | 2001 | 70 | 0.010 |
Why?
| Cytoplasm | 1 | 2001 | 89 | 0.010 |
Why?
| Estrogen Receptor beta | 1 | 2001 | 55 | 0.010 |
Why?
| src-Family Kinases | 1 | 2001 | 51 | 0.010 |
Why?
| Estrogen Receptor alpha | 1 | 2001 | 88 | 0.010 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 2001 | 155 | 0.010 |
Why?
| Deglutition Disorders | 1 | 2001 | 77 | 0.010 |
Why?
| Cell Nucleus | 1 | 2001 | 182 | 0.010 |
Why?
| Binding Sites | 1 | 2001 | 362 | 0.010 |
Why?
| Peptide Fragments | 1 | 2001 | 209 | 0.010 |
Why?
| Clinical Trials as Topic | 1 | 2002 | 486 | 0.010 |
Why?
| Estrogens | 1 | 2001 | 226 | 0.010 |
Why?
| Fibroblasts | 1 | 2001 | 336 | 0.010 |
Why?
| Sex Factors | 1 | 2001 | 712 | 0.010 |
Why?
| Osteoblasts | 1 | 2001 | 462 | 0.010 |
Why?
| Osteoclasts | 1 | 2001 | 427 | 0.010 |
Why?
| Apoptosis | 1 | 2001 | 1097 | 0.010 |
Why?
| Oligodeoxyribonucleotides | 1 | 1993 | 33 | 0.010 |
Why?
| Mutagenesis, Site-Directed | 1 | 1993 | 95 | 0.010 |
Why?
| RNA, Messenger | 1 | 1993 | 1089 | 0.010 |
Why?
| Cell Line | 1 | 1993 | 988 | 0.010 |
Why?
| DNA | 1 | 1993 | 535 | 0.010 |
Why?
|
|
Bodenner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|